CA2255888A1 - Modulation de l'activite d'hormones ou de leurs recepteurs - peptides, anticorps, vaccins et utilisations correspondantes - Google Patents

Modulation de l'activite d'hormones ou de leurs recepteurs - peptides, anticorps, vaccins et utilisations correspondantes Download PDF

Info

Publication number
CA2255888A1
CA2255888A1 CA002255888A CA2255888A CA2255888A1 CA 2255888 A1 CA2255888 A1 CA 2255888A1 CA 002255888 A CA002255888 A CA 002255888A CA 2255888 A CA2255888 A CA 2255888A CA 2255888 A1 CA2255888 A1 CA 2255888A1
Authority
CA
Canada
Prior art keywords
peptide
animal
seq
hormone
immunised
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002255888A
Other languages
English (en)
Inventor
Norman L. Gerraty
Simon L. Westbrook
David J. Kingston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORTHSTAR BIOLOGICALS Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2255888A1 publication Critical patent/CA2255888A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des peptides immunogènes, que l'on ne rencontre pas à l'état naturel, et à des molécules réagissant immunologiquement avec ces peptides, qui modulent l'activité d'hormones ou de récepteurs d'hormones. Ces peptides sont basés sur des parties de somatostatine, sur des récepteurs de somatostatine et sur une protéine de liaison du facteur de croissance proche de l'insuline. L'invention se rapporte également à des procédés visant à moduler l'activité hormonale chez un animal ainsi qu'à des compositions utilisées à cet effet.
CA002255888A 1996-05-22 1997-05-22 Modulation de l'activite d'hormones ou de leurs recepteurs - peptides, anticorps, vaccins et utilisations correspondantes Abandoned CA2255888A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPN9990A AUPN999096A0 (en) 1996-05-22 1996-05-22 Peptides, antibodies, vaccines & uses thereof
AUPN9990 1996-05-22
PCT/AU1997/000312 WO1997044352A1 (fr) 1996-05-22 1997-05-22 Modulation de l'activite d'hormones ou de leurs recepteurs - peptides, anticorps, vaccins et utilisations correspondantes

Publications (1)

Publication Number Publication Date
CA2255888A1 true CA2255888A1 (fr) 1997-11-27

Family

ID=3794302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002255888A Abandoned CA2255888A1 (fr) 1996-05-22 1997-05-22 Modulation de l'activite d'hormones ou de leurs recepteurs - peptides, anticorps, vaccins et utilisations correspondantes

Country Status (8)

Country Link
EP (1) EP1012171A1 (fr)
JP (1) JP2000512130A (fr)
CN (1) CN1226896A (fr)
AU (1) AUPN999096A0 (fr)
BR (1) BR9709038A (fr)
CA (1) CA2255888A1 (fr)
NZ (1) NZ332926A (fr)
WO (1) WO1997044352A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094124A2 (fr) * 2001-05-18 2002-11-28 Arkion Life Sciences Procede permettant d'accroitre l'uniformite de poids chez des oiseaux
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
JP2007535895A (ja) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
FR2874156B1 (fr) * 2004-08-13 2007-04-06 Univ Rennes 1 Etablissement Pu Complement alimentaire pour animaux d'elevage et procede de mise en oeuvre de celui-ci
MX2007006640A (es) 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
EP2100614B8 (fr) 2005-06-17 2013-11-20 ImClone LLC Anticorps contre PDGFR-alpha pour l'utilisation dans le traitement de tumeurs
ES2937113T3 (es) * 2006-01-20 2023-03-24 Starpharma Pty Ltd Macromolécula modificada
EA017265B1 (ru) 2006-02-03 2012-11-30 Имклоун Элэлси Применение антитела imc-a12, которое является ингибитором igf-ir, для лечения рака предстательной железы
MX2010014078A (es) * 2008-06-25 2011-04-11 Braasch Biotech Llc Composiciones y metodos para inmunogenecidad mejorada de somatostatina.
WO2014110601A1 (fr) 2013-01-14 2014-07-17 Xencor, Inc. Nouvelles protéines hétérodimères
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
ME03666B (fr) 2014-03-28 2020-10-20 Xencor Inc Anticorps bispécifiques se liant à cd38 et cd3
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
KR20170084326A (ko) 2014-11-26 2017-07-19 젠코어 인코포레이티드 Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
EP4257613A3 (fr) 2016-06-14 2023-12-13 Xencor, Inc. Anticorps inhibiteurs de points de contrôle bispécifiques
EP3475304B1 (fr) * 2016-06-28 2022-03-23 Xencor, Inc. Anticorps hétérodimériques qui se lient au récepteur 2 de la somatostatine
WO2021231976A1 (fr) 2020-05-14 2021-11-18 Xencor, Inc. Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
IL305736A (en) 2021-03-09 2023-11-01 Xencor Inc Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (fr) 2021-03-10 2024-01-17 Xencor, Inc. Anticorps hétérodimères qui se lient au cd3 et au gpc3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH647246A5 (en) * 1981-03-06 1985-01-15 Sandoz Ag Polypeptide derivatives, their preparation and pharmaceutical products which contain these polypeptide derivatives
CH679045A5 (fr) * 1987-06-29 1991-12-13 Sandoz Ag
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
JPH0782162A (ja) * 1993-09-10 1995-03-28 Pola Chem Ind Inc 皮膚外用剤

Also Published As

Publication number Publication date
JP2000512130A (ja) 2000-09-19
CN1226896A (zh) 1999-08-25
WO1997044352A1 (fr) 1997-11-27
EP1012171A1 (fr) 2000-06-28
BR9709038A (pt) 2000-01-04
NZ332926A (en) 2000-08-25
AUPN999096A0 (en) 1996-06-13

Similar Documents

Publication Publication Date Title
CA2255888A1 (fr) Modulation de l'activite d'hormones ou de leurs recepteurs - peptides, anticorps, vaccins et utilisations correspondantes
JP5231378B2 (ja) 免疫原性ｌｈｒｈ組成物およびそれに関する方法
EP0833658B1 (fr) Compositions a base d'inhibine et procedes destines a accroitre la production
US20020169116A1 (en) Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
US5786179A (en) Heterologous protein comprising avian alpha-subunit inhibin protein and methods of producing same
WO1988000056A1 (fr) Composition et procede de castration et de sterilisation immunologiques
AU738528B2 (en) Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
NZ337256A (en) Pharmaceutical carrier derived from deep sea shark oil and uses thereof
AU5773901A (en) Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
RU2722849C1 (ru) Рекомбинантный белок GBD-SSTad-SSTad, способ его получения и применения
JPH08154957A (ja) 牛の過剰排卵誘起方法
Turkstra et al. Active immunisation against gonadotropin-releasing hormone, an active tool to block the fertility axis in mammals
US20040220098A1 (en) Inhibin compositions and methods of enhancing fertility and growth
AU643444B2 (en) SRIF-related peptides and uses thereof
US20030171283A1 (en) Inhibin compositions and methods of enhancing production performance
AU7642387A (en) Composition and method for immunological castration and spaying
AU5660300A (en) Inhibin compositions and methods of enhancing production performance
Scaramuzzi et al. The implications of immunological techniques for the improvement of production efficiency in pigs.
MXPA97009579A (en) Inhibit compositions and methods to improve producc's performance

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued